nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy
|
Henricks, Linda M. |
|
2019 |
107 |
C |
p. 60-67 |
artikel |
2 |
An open-label, multicentre safety study of vemurafenib in patients with BRAF V600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
|
Larkin, James |
|
2019 |
107 |
C |
p. 175-185 |
artikel |
3 |
A novel risk calculator to predict outcome after surgery for symptomatic spinal metastases; use of a large prospective patient database to personalise surgical management
|
Choi, David |
|
2019 |
107 |
C |
p. 28-36 |
artikel |
4 |
Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials
|
Chau, Ian |
|
2019 |
107 |
C |
p. 115-123 |
artikel |
5 |
Changes in FIT values below the threshold of positivity and short-term risk of advanced colorectal neoplasia: Results from a population-based cancer screening program
|
Buron, Andrea |
|
2019 |
107 |
C |
p. 53-59 |
artikel |
6 |
Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers
|
Downs, Bradley |
|
2019 |
107 |
C |
p. 68-78 |
artikel |
7 |
Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning
|
Suchorska, Bogdana |
|
2019 |
107 |
C |
p. 15-27 |
artikel |
8 |
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
|
Kanjanapan, Y. |
|
2019 |
107 |
C |
p. 1-7 |
artikel |
9 |
Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab
|
Noda-Narita, Shoko |
|
2019 |
107 |
C |
p. 93-96 |
artikel |
10 |
Dramatic response of nivolumab-associated psoriasiform dermatitis to etoposide
|
Rios, Adan |
|
2019 |
107 |
C |
p. 97-99 |
artikel |
11 |
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
|
Zandberg, Dan P. |
|
2019 |
107 |
C |
p. 142-152 |
artikel |
12 |
Establishing the European Norm for the health-related quality of life domains of the computer-adaptive test EORTC CAT Core
|
Liegl, G. |
|
2019 |
107 |
C |
p. 133-141 |
artikel |
13 |
General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States
|
Nolte, S. |
|
2019 |
107 |
C |
p. 153-163 |
artikel |
14 |
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
|
Hasan Ali, Omar |
|
2019 |
107 |
C |
p. 8-14 |
artikel |
15 |
Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
|
von Pawel, J. |
|
2019 |
107 |
C |
p. 124-132 |
artikel |
16 |
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)
|
Watson, S. |
|
2019 |
107 |
C |
p. 46-52 |
artikel |
17 |
Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre
|
Ruatta, F. |
|
2019 |
107 |
C |
p. 79-85 |
artikel |
18 |
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
|
Hakenberg, Oliver W. |
|
2019 |
107 |
C |
p. 186-195 |
artikel |
19 |
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase
|
Schwartz, Sarit |
|
2019 |
107 |
C |
p. 164-174 |
artikel |
20 |
Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial
|
Suenaga, Mitsukuni |
|
2019 |
107 |
C |
p. 100-114 |
artikel |
21 |
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)
|
Retz, Margitta |
|
2019 |
107 |
C |
p. 37-45 |
artikel |
22 |
Topographical distribution of sentinel nodes and metastases from T1–T2 oral squamous cell carcinomas
|
Mølstrøm, Jacob |
|
2019 |
107 |
C |
p. 86-92 |
artikel |